TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare ConferenceGlobeNewsWire • 09/02/21
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/12/21
TRACON Pharmaceuticals ends 2Q with $25.6M; remains on track to reveal interim ENVASARC trial data in 2021Proactive Investors • 08/11/21
TRACON Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/11/21
TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal TrialGlobeNewsWire • 08/09/21
TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology ConferenceGlobeNewsWire • 08/03/21
TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021GlobeNewsWire • 07/28/21
TRACON Pharmaceuticals upsizes bought deal offering of stock to $15M due to strong demandProactive Investors • 07/22/21
TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 MillionGlobeNewsWire • 07/22/21
TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common StockGlobeNewsWire • 07/21/21
TRACON Pharmaceuticals appoints new senior vice president of regulatory affairs and grants inducement equity awardProactive Investors • 07/20/21
TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement AwardGlobeNewsWire • 07/20/21
TRACON Pharmaceuticals announces appointment of Ya Huang as executive director of Statistical ProgrammingProactive Investors • 06/30/21
TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Granting of Inducement AwardGlobeNewsWire • 06/30/21
TRACON Pharmaceuticals announces orphan drug designation for envafolimab in soft tissue sarcoma.Proactive Investors • 06/29/21
TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue SarcomaGlobeNewsWire • 06/29/21
TRACON Pharmaceuticals presents Phase 1 study data of uliledlimab and atezolizumab at American Society of Clinical Oncology meetingProactive Investors • 06/04/21
TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual MeetingGlobeNewsWire • 06/04/21
TRACON Pharmaceuticals says ENVASARC trial to proceed as planned after Independent Data Monitoring Committee recommendationProactive Investors • 06/01/21
TRACON Pharmaceuticals to Present at the Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/25/21
TRACON Pharmaceuticals Announces Poster Presentations at the 2021 ASCO Virtual Annual MeetingGlobeNewsWire • 05/20/21
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
TRACON Pharmaceuticals ends 1Q with $30.4M to fund its cancer drug trialsProactive Investors • 05/05/21